Compared with placebo or other interventions, GLP-1 receptor agonist use showed no association with an increased risk of neoplasm development (OR 1.04, 95% CI 0.94–1.15; p = 0.46), with no statistically significant between-study heterogeneity (I2 = 0%, p = 0.91; Figure 2). Here, GLP1R is linked to neoplasm.